Dosage Forms

Articles

The company expanded its topicals capacity with an investment in the Becomix RW30 model homogenizer.

Juniper Pharma Services Expands Topicals Capacity

The agency publishes draft guidance on assessing the adhesion of transdermal delivery systems and topical patches.

FDA Releases Guidance on Topical Patches

The agency found no differences in risk of pneumonia for different products.

EMA Completes Review of Inhaled Corticosteriods

Novartis announced on Jan. 5, 2016 that the company is collaborating with Qualcomm to develop cloud-based technology for COPD patients.

Novartis Announces Cloud Technology in Development for Inhalers

Ionis Pharmaceuticals receives orphan drug designation for HTTRx for the treatment of Huntington’s disease.

Ionis Pharmaceuticals Receives Orphan Drug Designation for HTTRx

3M and Impel will collaborate to develop and commercialize Impel’s Precision Olfactory Delivery technology for enhanced central nervous system drug delivery.

Impel and 3M Partner to Advance Olfactory Drug Delivery

The agency has set up a workshop on how to demonstrate the benefits of orphan drugs over existing treatments.

EMA Sets Up Workshop on Orphan Drugs

Andrew Teasdale, PhD, is a Principle Scientist at AstraZeneca.

Katherine Ulman is a Global Regulatory Compliance Manager at Dow Corning.

Phyllis Walsh is a senior compendial manager at Schering-Plough Corporation in Kenilworth, New Jersey.

EHS specialist at Dow Corning Corporation, Auburn, MI

Current guidance for absorption of elemental impurities does not address dermal exposure, resulting in a simplistic approach to limit setting.

Establishing Limits for Dermal Absorption of Elemental Impurities

Successful drug delivery via a dry powder inhaler is determined by the API physicochemical properties, the formulation composition and process, the device and operating conditions, the patient–device relationship, the environmental variables, and ultimately, patient compliance.

Developing an Orally Inhaled Dry Powder Formulation—A Complex Itinerary and a Technological Challenge

Pharmaceutical Technology spoke with David Fitzhenry about the costs of specialty drugs.

Specialty Dosage Drugs